Search research articles
Contact Us
Filters
Showing results (471-480 of 567) with videos related to
Page
of 57
Sort By:
European Urology
|
April 16, 2017
Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025
Bernard Escudier, Robert J Motzer, Padmanee Sharma, et al.
Cancer
|
April 30, 2009
Innovations and challenges in renal cancer: summary statement from the Third Cambridge Conference
Michael B Atkins, Ronald M Bukowski, Bernard J Escudier, et al.
Annals of the Rheumatic Diseases
|
May 21, 2013
Evidence of NLRP3-inflammasome activation in rheumatoid arthritis (RA); genetic variants within the NLRP3-inflammasome complex in relation to susceptibility to RA and response to anti-TNF treatment
Rebeccah J Mathews, James I Robinson, Michele Battellino, et al.
British Journal of Haematology
|
May 21, 2024
Inflammatory profile of lower risk myelodysplastic syndromes
Joanne Topping, Adele Taylor, Fatima Nadat, et al.
European Urology
|
March 7, 2017
CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma
Bernard Escudier, Padmanee Sharma, David F McDermott, et al.
Frontiers in Microbiology
|
July 11, 2022
Prevalence of Antimicrobial Resistance in Select Bacteria From Retail Seafood-United States, 2019
Heather Tate, Sherry Ayers, Epiphanie Nyirabahizi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 2, 2021
Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma
David F McDermott, Jae-Lyun Lee, Marek Ziobro, et al.
Journal for Immunotherapy of Cancer
|
July 26, 2024
Treatment-free survival and partitioned survival analysis of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib: 5-year update of CheckMate 214
Charlene M Mantia, Opeyemi A Jegede, Elizabeth R Plimack, et al.
Journal for Immunotherapy of Cancer
|
November 20, 2024
Nemvaleukin alfa, a modified interleukin-2 cytokine, as monotherapy and with pembrolizumab in patients with advanced solid tumors (ARTISTRY-1)
Ulka N Vaishampayan, Jameel Muzaffar, Ira Winer, et al.
Journal for Immunotherapy of Cancer
|
December 21, 2019
The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)
Brian I Rini, Dena Battle, Robert A Figlin, et al.
Page
of 57
Search research articles
Search
Showing results (471-480 of 567) with videos related to
Sort By:
Page
of 57
European Urology
|
April 16, 2017
Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025
Bernard Escudier, Robert J Motzer, Padmanee Sharma, et al.
Cancer
|
April 30, 2009
Innovations and challenges in renal cancer: summary statement from the Third Cambridge Conference
Michael B Atkins, Ronald M Bukowski, Bernard J Escudier, et al.
Annals of the Rheumatic Diseases
|
May 21, 2013
Evidence of NLRP3-inflammasome activation in rheumatoid arthritis (RA); genetic variants within the NLRP3-inflammasome complex in relation to susceptibility to RA and response to anti-TNF treatment
Rebeccah J Mathews, James I Robinson, Michele Battellino, et al.
British Journal of Haematology
|
May 21, 2024
Inflammatory profile of lower risk myelodysplastic syndromes
Joanne Topping, Adele Taylor, Fatima Nadat, et al.
European Urology
|
March 7, 2017
CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma
Bernard Escudier, Padmanee Sharma, David F McDermott, et al.
Frontiers in Microbiology
|
July 11, 2022
Prevalence of Antimicrobial Resistance in Select Bacteria From Retail Seafood-United States, 2019
Heather Tate, Sherry Ayers, Epiphanie Nyirabahizi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 2, 2021
Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma
David F McDermott, Jae-Lyun Lee, Marek Ziobro, et al.
Journal for Immunotherapy of Cancer
|
July 26, 2024
Treatment-free survival and partitioned survival analysis of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib: 5-year update of CheckMate 214
Charlene M Mantia, Opeyemi A Jegede, Elizabeth R Plimack, et al.
Journal for Immunotherapy of Cancer
|
November 20, 2024
Nemvaleukin alfa, a modified interleukin-2 cytokine, as monotherapy and with pembrolizumab in patients with advanced solid tumors (ARTISTRY-1)
Ulka N Vaishampayan, Jameel Muzaffar, Ira Winer, et al.
Journal for Immunotherapy of Cancer
|
December 21, 2019
The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)
Brian I Rini, Dena Battle, Robert A Figlin, et al.
Page
of 57